UBS chief's surprise return to the Swiss banking giant bagged him a $15.9 million paycheck
https://www.cnbc.com/2024/03/28/ubs-chiefs-surprise-return-to-the-swiss-banking-giant-bagged-him-a-15point9-million-paycheck.html
Mar 28, 2024 - UBS CEO Sergio Ermotti earned 14.4 million Swiss francs ($15.9 million) in 2023 after his surprise return to the helm of the Swiss banking giant.
0
UBS Group (UBS) to Undergo Two Stress Tests in '24 by FINMA
https://www.zacks.com/stock/news/2245113/ubs-group-ubs-to-undergo-two-stress-tests-in-24-by-finma?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2245113
Mar 22, 2024 - Amid heightening concerns over its increased balance sheet, UBS Group (UBS) is subjected to two stress tests this year along with around 40 reviews by FINMA.
0
UBS Group (UBS) Seeks Wealth Management Growth in the US
https://www.zacks.com/stock/news/2242415/ubs-group-ubs-seeks-wealth-management-growth-in-the-us?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2242415
Mar 18, 2024 - UBS Group (UBS) seeks merger and acquisition opportunities in the United States to expand its wealth management footprint in the country.
0
UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates
https://seekingalpha.com/news/4079564-ubs-sees-lilly-glp-1sleep-apnea-study-falling-short-of-street-estimates?source=feed_sector_healthcare
Mar 14, 2024 - UBS said it believes that upcoming data for Eli Lilly’s (LLY) GLP-1 drug tirzepatide in the treatment of sleep apnea will come in below Street expectations. Read more here.
0
UBS (UBS) Up 5% Since Last Earnings Report: Can It Continue?
https://www.zacks.com/stock/news/2237436/ubs-ubs-up-5-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-realtime_blog-2237436
Mar 07, 2024 - UBS (UBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
UBS Group AG (UBS) Aided by Strategic Buyouts Amid High Costs
https://www.zacks.com/stock/news/2232509/ubs-group-ag-ubs-aided-by-strategic-buyouts-amid-high-costs?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2232509
Feb 27, 2024 - Business restructuring plans and strategic acquisitions support UBS Group AG's (UBS) financials. However, rising costs will likely limit bottom-line growth.
0
UBS cuts BioXcel to neutral; cites regulatory issues, financing
https://seekingalpha.com/news/4069650-ubs-cuts-bioxcel-to-neutral-cites-regulatory-issues-financing?source=feed_sector_healthcare
Feb 21, 2024 - UBS has downgraded BioXcel Therapeutics (BTAI) to neutral, citing too much uncertainty about the company’s financing, regulatory alignment with the FDA, and end
0
Alkermes downgraded at UBS as stock nears 52-week high
https://seekingalpha.com/news/4069051-alkermes-downgraded-ubs-stock-nears-52-week-high?source=feed_sector_healthcare
Feb 20, 2024 - UBS downgrades Alkermes to sell due to disappointing sales and negative pipeline update. Read more here.
0
Nvidia: UBS Note Should Raise Alarms
https://seekingalpha.com/article/4670524-nvidia-ubs-note-should-raise-alarms?source=feed
Feb 15, 2024 - UBS raises Nvidia's (NVDA) earnings estimates and price target, but warns of near-term trouble for growth due to decreased lead times. Learn why it is posing a risk for investors.
0
UBS starts Axsome at buy, sees Auvelity hitting $1B sales by 2030
https://seekingalpha.com/news/4064942-ubs-starts-axsome-at-buy-sees-auvelity-hitting-1b-sales-by-2030?source=feed_sector_healthcare
Feb 08, 2024 - UBS has initiated coverage of Axsome Therapeutics (AXSM) with a buy rating, commenting that it was bullish on the launch of the company’s drug Auvelity and upco
0